🔗 Share this article The Global Health Body Raises Concern Over Critical Shortage of Obesity Medications Under 10% of people that would benefit from weight-loss injections including Wegovy have access to them, warns the global health agency as it issues its inaugural advice on the medications. Considering over a billion people worldwide currently obese, it is calling for broader and more equitable access to this class of drugs. Based on estimates, over two billion will be obese by 2030 if no action is taken. "The latest guidance acknowledges that obesity is a long-term condition that can be treated with thorough and lifelong treatment," remarked WHO director-general Tedros Adhanom Ghebreyesus. Substantial prices, constrained manufacturing, and logistical bottlenecks are significant hurdles to widespread access to the jabs that can help people shift significant weight, explains the organization. Skinny Jab Scarcity Despite the current most favorable case, the production of these medications might only reach around 100 million people – fewer than 10% of the global need, as stated by the WHO. The recommendation urges governments and firms to increase availability, by approaches such as licensing agreements. Exclusive production rights on a key compound – the primary ingredient of the drug Wegovy – is due to expire in a number of nations in 2026. How Weight-Loss Injections Work These medications mimick a body's own hormone to reduce digestion speed, reduce hunger and enhance satiety so individuals reduce food intake. Individuals typically start to lose weight in the initial weeks of starting on the weekly injections. Evidence suggests patients may put most of the weight back on a year later of discontinuing the treatment, because their typical hunger resume. To be overweight or obese elevates your likelihood for contracting health problems, including type 2 diabetes, heart disease, brain attack, and specific cancers. Excess weight impacts people in all nations and was responsible for millions of fatalities worldwide in 2024, per the WHO.
Under 10% of people that would benefit from weight-loss injections including Wegovy have access to them, warns the global health agency as it issues its inaugural advice on the medications. Considering over a billion people worldwide currently obese, it is calling for broader and more equitable access to this class of drugs. Based on estimates, over two billion will be obese by 2030 if no action is taken. "The latest guidance acknowledges that obesity is a long-term condition that can be treated with thorough and lifelong treatment," remarked WHO director-general Tedros Adhanom Ghebreyesus. Substantial prices, constrained manufacturing, and logistical bottlenecks are significant hurdles to widespread access to the jabs that can help people shift significant weight, explains the organization. Skinny Jab Scarcity Despite the current most favorable case, the production of these medications might only reach around 100 million people – fewer than 10% of the global need, as stated by the WHO. The recommendation urges governments and firms to increase availability, by approaches such as licensing agreements. Exclusive production rights on a key compound – the primary ingredient of the drug Wegovy – is due to expire in a number of nations in 2026. How Weight-Loss Injections Work These medications mimick a body's own hormone to reduce digestion speed, reduce hunger and enhance satiety so individuals reduce food intake. Individuals typically start to lose weight in the initial weeks of starting on the weekly injections. Evidence suggests patients may put most of the weight back on a year later of discontinuing the treatment, because their typical hunger resume. To be overweight or obese elevates your likelihood for contracting health problems, including type 2 diabetes, heart disease, brain attack, and specific cancers. Excess weight impacts people in all nations and was responsible for millions of fatalities worldwide in 2024, per the WHO.